Related Experiment Video
Updated: Aug 8, 2026
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Lobenzarit disodium (CCA) inhibits in vitro immunoglobulin production via direct interaction with B lymphocytes
Y Takeda1, K Urakawa, A Sakamoto
1Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan.
Insights
Lobenzarit disodium (CCA) inhibits immunoglobulin production in rheumatoid arthritis patients by targeting B lymphocyte proliferation. It enhances early B cell activation but suppresses later stages, impacting antibody secretion.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint destruction.
- Immunoglobulin production by B lymphocytes plays a critical role in the pathogenesis of RA.
- Lobenzarit disodium (CCA) is a therapeutic agent investigated for its effects on RA.
Purpose of the Study:
- To investigate the in vitro regulatory effects of lobenzarit disodium (CCA) on polyclonal immunoglobulin production by human lymphocytes.
- To determine the specific B lymphocyte activation stage targeted by CCA.
Main Methods:
- In vitro culture of human lymphocytes with lobenzarit disodium (CCA).
- Assessment of immunoglobulin production across all classes.
- Culture of preactivated B lymphocytes with recombinant lymphokines (IL2, IL6).
- Analysis of B lymphocyte activation at primary and proliferation-differentiation stages.
Main Results:
- CCA significantly inhibited immunoglobulin production in all examined classes at clinically relevant concentrations.
- CCA suppressed immunoglobulin production and lymphocyte proliferation even in preactivated B lymphocytes stimulated with IL2 and IL6.
- CCA was found to augment, not inhibit, B lymphocytes at the primary activation stage.
- CCA specifically inhibits the proliferation and differentiation stage of B lymphocytes.
Conclusions:
- Lobenzarit disodium (CCA) exerts direct regulatory effects on human B lymphocytes.
- CCA's mechanism involves inhibiting the proliferation and differentiation of B lymphocytes into antibody-secreting cells.
- CCA's dual action—enhancing early activation while inhibiting later stages—offers a novel therapeutic approach for rheumatoid arthritis.
Abstract:
The regulatory effects of lobenzarit disodium (CCA), a therapeutic agent for treating rheumatoid arthritis (RA), on polyclonal immunoglobulin production by human lymphocytes were investigated in vitro. CCA inhibited the production of immunoglobulin in all the classes examined at a clinically relevant concentration. Moreover, it inhibited the immunoglobulin production as well as lymphocyte proliferation even when purified B lymphocytes preactivated by Staphylococcus aureus COWAN I were cultured with recombinant lymphokines such as IL2 and IL6. These results suggest that CCA acts directly on B lymphocytes. The analysis at each of two different stages of B lymphocyte activation lineage, i.e., the primary activation stage and a stage of proliferation and differentiation to antibody secreting cells, has indicated that CCA inhibits the proliferation-differentiation stage of B lymphocytes. CCA does not inhibit B lymphocytes at the primary activation stage; actually, it augments them, resulting in the subsequent enhancement of immunoglobulin production.
More Related Videos
09:11Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection
Published on: July 16, 2019
14:18Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
